This is the authors' abstract. We don't add key points for this paper.
The objective of this study was to ascertain the prevalence of PIK3CA mutations and PTEN loss in HER2-positive stage II–III Vietnamese breast cancer patients and evaluate their impact on the disease. This case-control study, conducted from January 2019 to June 2022, included 92 patients initially diagnosed with stage II or III breast cancer, confirmed HER2-positive, and treated with neoadjuvant trastuzumab. Post-mastectomy, patients were grouped into pathological complete response (pCR) and path
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: